The study consists of a screening visit, a treatment phase of one study period and a final visit/early termination visit (ETV).
For each subject, two DHEP-Heparin medicated plasters are applied concurrently as follows: one plaster without reinforcement (PW) and one plaster with reinforcement (PR) are applied to the right and left side of the upper back (dorsal region, below the scapula), with the longer side parallel to the spine, at the same height, as near as possible to the spine. Plaster for PR treatment was reinforced using small pieces of tape applied to the four corners of the DHEP-Heparin plaster.
The investigator assesses each plaster adhesion at 4, 8, 12, 16, 20 and 24 h post-application using the following 5-point scale, according to the FDA Guidance for Assessing adhesion.
In addition, at each time point, when adhesion was assessed on the 5-point scale, the actual percentage adherence value (%) was estimated by the investigator and reported in the CRF.
The two assessments (score and actual percentage evaluation) are visually performed by a an experienced and trained scorer (the Principal Investigator) who was previously involved as investigator in several clinical trials where visual evaluation of patch detached area was part of study assessments.
Standardised digital photographs are taken before application and at each assessment time for each plaster.
After adhesion assessment and photograph, at each assessment time the shapes of attachment/detachment area of each plaster were traced on an acetate sheet in order to collect an additional image of the detached area of each plaster.
Each plaster contained 181 mg DHEP corresponding to 140 mg diclofenac sodium. Therefore, the subjects are exposed to a total dose of approximately 280 mg diclofenac sodium.
The randomisation list is computer-generated by the Department of Biometry at the Contract Research Organization (CRO) using the PLAN procedure of the validated SAS for Windows Version 9.1.3 Serv